Related Experiment Video
Updated: May 29, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program
Malcolm A Smith1, Richard Gorlick, E Anders Kolb
1Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland, USA. Malcolm.Smith@nih.gov
None:
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.
More Related Videos
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Teratogenicity
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Bioavailability Study Design: Healthy Subjects Versus Patients

